Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy

Montoya, Carlos; Toro, María Eugenia; Aguirre, Carlos; Bustamante, Alberto; Hernández, Manuel Hernández; Arango, Liliana; Echeverry, M.; Arango, Ana E.; Prada, M. Claudia; Alarcon, Herminia del P; Rojas, Mauricio

doi:10.1590/s0074-02762007005000055

Cited by 21 publications

(10 citation statements)

References 25 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…79 The role of HIV-1 viral load for the influenza vaccination outcome is unclear as an association between viral load and immune response was reported in one study but not in another. 60,82 On the other hand, age and CD4+ T-cell counts do not seem to play a role. 79,83 During 2009, an upcoming pandemic infection of humans with swine influenza virus A(H1N1) was announced by WHO and a massive vaccination campaign was undertaken with both killed virus vaccines and live attenuated nasal sprays.…”

Section: Adaptive Immune Response To Different Vaccine Typesmentioning

confidence: 98%

“…80 In general, protective responses to different inactivated seasonal influenza vaccines in HIV-1 infected children, even if treated with HAART, are lower compared with healthy controls. 79,[81][82][83] The percentage of initial responders ranges 50-100% and in some cases, antibodies are almost completely lost after 6 mo from vaccination. 83 However, the establishment of CD8 + interferon-γ-secreting T-cells together with CD4 + interleukin (IL)-2-secreting T-cells upon vaccination may be more important than antibody formation as increase for influenza specific IgG3 but not IgG1 was reported.…”

Section: Adaptive Immune Response To Different Vaccine Typesmentioning

confidence: 99%

See 1 more Smart Citation

Immune reconstitution and vaccination outcome in HIV-1 infected children

Cagigi

Cotugno

Giaquinto

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Adaptive Immune Response To Different Vaccine Typesmentioning

confidence: 98%

Section: Adaptive Immune Response To Different Vaccine Typesmentioning

confidence: 99%

Immune reconstitution and vaccination outcome in HIV-1 infected children

Cagigi

Cotugno

Giaquinto

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…22,23 Compared with healthy individuals, HIV-infected individuals often have reduced immune responses to various immunisations (e.g. influenza vaccination, 24,25 hepatitis B virus vaccination 26 and pneumococcal vaccination 27 ). Nevertheless, vaccination remains a common clinical tool to reduce the risk of secondary infections in people with HIV.…”

Section: Introductionmentioning

confidence: 99%

Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives

et al. 2014

View full text Add to dashboard Cite

Abstract. Background: Men and women with HIV infection are at increased risk of developing cancers associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines protect against de novo infection with HPV-16 and HPV-18, which cause the majority of HPV-associated cancers. Currently, no vaccine efficacy data are available for persons with HIV infection. Nevertheless, some countries have implemented specific HPV vaccination recommendations for HIV-positive populations. To specifically recommend prophylactic HPV vaccination in people with HIV, the vaccines must be safe and immunogenic in immunosuppressed people at a high risk of HPV infection. This review aims to summarise the current knowledge from published HPV vaccine trials in HIV-infected populations, to compile scheduled and ongoing HPV vaccine trials with HIV-positive study populations and to extrapolate the relevant knowledge about HPV vaccine efficacy in HIV-negative populations to an HIV context. Methods: The databases PubMed, Scopus and ClinicalTrials.gov were searched for peer-reviewed articles and scheduled or ongoing clinical HPV vaccine trials enrolling HIV-positive persons. Results: Current data indicate that prophylactic HPV vaccines are safe and immunogenic in different HIV-positive populations (children, female adolescents, adults). Increased immunogenicity has been reported in persons on antiretroviral therapy compared with antiretroviral-naïve persons, whereas no clear association has been found between CD4+ cell count at immunisation and vaccine response. Several scheduled and ongoing HPV vaccine trials aim to determine vaccine efficacy against disease endpoints in HIV-infected study populations. Conclusion:Prophylactic HPV vaccination appears safe, immunogenic and, by extrapolation, likely to reduce HPVassociated cancer development among persons with HIV infection.

show abstract

“…In HIV-uninfected subjects 9-17 years of age who were immunized with 15 µg or 30 µg of the same unadjuvanted vaccine given to Group B in the current study, 96% and 100%, respectively, achieved HAI antibody titers 40 [18]. Multiple other studies have reported lower immunogenicity of influenza vaccines and lower proportions of HIV-infected vaccinees achieving protective HAI antibody titers than in persons without HIV infection [5,8,11,[21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 43%

“…In addition, an association between poor response to influenza vaccines and higher viral load and/or lower current or nadir CD4 counts has been reported [21,[29][30][31]. Studies of AS03-and MF59-adjuvanted vaccines in healthy adults and children report higher rates of seroprotection and seroconversion or achievement of comparable immunogenicity with much smaller doses of antigen with adjuvanted vaccine [18,20,32,33].…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth

Pass

Nachman²,

Flynn

et al. 2013

Journal of the Pediatric Infectious Diseases Society

View full text Add to dashboard Cite

Background. With the emergence of pandemic influenza A ( pH1N1) in 2009, children and youth infected with human immunodeficiency virus (HIV) were vulnerable because of immunologic impairment and the greater virulence of this infection in young persons. Methods. A multicenter study of the immunogenicity of 3 licensed influenza A (H1N1) monovalent vaccines (1 live attenuated and 2 inactivated) was conducted in children and youth with perinatal HIV infection, most of whom were receiving 3 antiretroviral drugs, had CD4% 15, and plasma HIV RNA levels <400 copies/mL. Serum hemagglutinin inhibition assay (HAI) antibody levels were measured and correlated with baseline demographic and clinical variables. Results. One hundred forty-nine subjects were enrolled at 26 sites in the United States and Puerto Rico. Over 40% had baseline HAI titers 40. For subjects aged 6 months to <10 years, 79% and 68%, respectively, achieved a 40-and 4-fold rise in HAI titers after the second dose of vaccine. Three weeks after a single immunization with an inactivated vaccine, similar immunogenicity results were achieved in youth aged 10-24 years. With multivariable analysis, only Hispanic ethnicity and CD4% 15 were associated with achieving both HAI titer 40-and 4-fold rise in titer. Conclusions. Although licensed pH1N1 vaccines produced HAI titers that were considered to be protective in the majority of HIV-infected children and youth, the proportion with titers 40-and 4-fold rise in titer was lower than expected for children without HIV infection. Vaccine immunogenicity was lower in HIV-infected children and youth with evidence of immune suppression.

show abstract

Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy

Abstract: Given that highly active antiretroviral therapy (HAART)

Cited by 21 publications

References 25 publications

Immune reconstitution and vaccination outcome in HIV-1 infected children

Immune reconstitution and vaccination outcome in HIV-1 infected children

Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives

Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth

Contact Info

Product

Resources

About